KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.

Sofia Ramiro, Denis Poddubnyy, Philip J Mease, Clementina López-Medina, Mindy Kim, Ute Massow, Vanessa Taieb, Tue Wenzel Kragstrup, Dennis McGonagle

RMD Open 11(4) e005969

PMID41125403
PMCIDPMC12550279
DOI10.1136/rmdopen-2025-005969
发表日期2025-10-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies. OBJECTIVE: Assess the impact of BKZ on peripheral manifestations to week 104 of those studies. METHODS: BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) each comprised a 16-week double-blind, placebo-controlled period, then all received BKZ 160 mg every 4 weeks for 36 weeks. Patients not meeting withdrawal criteria could enter a combined open-label extension. We report change in enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)) in patients with baseline MASES>0, peripheral arthritis (swollen joint count (SJC)/Disease Activity Index for Psoriatic Arthritis (DAPSA)) in patients with baseline SJC>0 and proportions achieving DAPSA disease states to week 104. Resolution of enthesitis (MASES=0)/arthritis (SJC=0) is reported to week 104 for those with baseline enthesitis/arthritis. We also report associations between peripheral manifestation resolution (MASES=0/SJC=0) and week 104 clinical outcomes in those with baseline enthesitis/arthritis. RESULTS: At baseline, 186/254 (73.2%) and 88/254 (34.6%) patients with nr-axSpA had enthesitis (MASES>0) and arthritis (SJC>0), respectively, compared with 199/332 (59.9%) and 66/332 (19.9%) patients with r-axSpA. Pooled BKZ/placebo-randomised patients with enthesitis (nr-axSpA/r-axSpA) showed average MASES improvement from 4.8/4.3 (baseline) to 1.6/1.3 (week 52) and 1.6/1.0 (week 104). Pooled BKZ/placebo-randomised patients with arthritis showed average SJC improvement from 4.0/4.5 (baseline) to 1.2/0.7 (week 52) and 0.9/0.6 (week 104). Over 60% of patients achieved DAPSA low disease activity/remission by week 52. Over 40%/60% patients achieved resolution of enthesitis (MASES=0)/arthritis (SJC=0) at week 104; enthesitis resolution was associated with larger improvements in week 104 clinical outcomes for patients with r-axSpA. CONCLUSION: BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Graphical summary of study results. a BKZ-randomised patients; b BKZ-randomised and placebo-switched patients; c placebo-randomised patients. axSpA, axial spondyloarthritis; BKZ, bimekizumab; DAPSA, Disease Activity Index in Psoriatic Arthritis; LDA, low disease activity; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; MI: multiple imputation; nr-axSpA: non-radiographic axSpA; NRI: non-responder imputation; OC: observed case; PBO: placebo; r-axSpA: radiographic axSpA; REM: remission; SJC: swollen joint count.

Mean_MASES_SEM_

MASES (Enthesitis)

Figure 1 · Panel Mean_MASES_SEM_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Mean_MASES_SEM_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Mean_SJC_SEM_

SJC (Swollen Joint Count)

Figure 1 · Panel Mean_SJC_SEM_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Mean_SJC_SEM_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Distribution at baseline of enthesitis by tendons and swollen joints (observed case). Randomised set. Labels indicate the percentage of patients with at least one swollen joint or enthesitis in at least one tendon of the mentioned type. The diameter of each shaded circle is proportional to the percentage of patients with at least one swollen joint or enthesitis in at least one tendon of that type; where fewer than 3% of patients reported a swollen joint or tendon in a certain area, circles remain the same size to ensure visibility. Enthesitis and swollen joint count were assessed in 44 joints. Left and right joints and tendons are grouped together. ACJ, acromioclavicular joint; axSpA, axial spondyloarthritis; BKZ, bimekizumab; IPJ, interphalangeal joint; MCPJ, metacarpophalangeal joint; MTPJ, metatarsophalangeal joint; nr-axSpA, non-radiographic axSpA; r-axSpA, radiographic axSpA; SCJ, sternoclavicular joint.
非 KM Figure
Figure 3Mean change from baseline in MASES to week 104 (multiple imputation) and proportion of patients achieving MASES=0 (non-responder imputation). Randomised set. MASES ranges from 0 to 13, with lower scores indicating less severe enthesitis and a negative change representing improvement. MASES is reported in study participants with enthesitis at baseline (MASES>0). Error bars represent 95% CIs. axSpA, axial spondyloarthritis; BKZ, bimekizumab; CfB, change from baseline; CI: confidence interval; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; r-axSpA, non-radiographic axSpA; PBO, placebo; r-axSpA, radiographic axSpA; Q4W, every 4 weeks.
非 KM Figure
Figure 4Mean change from baseline in SJC (multiple imputation) and DAPSA (observed case) to week 104. Randomised set (reported in patients with SJC>0 at baseline). SJC and TJC assessed in 44 joints. Error bars represent 95% CIs. axSpA, axial spondyloarthritis; BKZ, bimekizumab; CfB, change from baseline; CI: confidence interval; DAPSA, Disease Activity Index for Psoriatic Arthritis; nr-axSpA, non-radiographic axSpA; PBO, placebo; r-axSpA, radiographic axSpA; Q4W, every 4 weeks; SJC, swollen joint count.
非 KM Figure
Figure 5DAPSA disease states over time (observed case). Randomised set. Reported in patients with SJC>0 at baseline. REM: DAPSA≤4; LDA: DAPSA>4 to ≤14; MDA: DAPSA>14 to ≤28; and HDA: DAPSA>28. axSpA, axial spondyloarthritis; BKZ, bimekizumab; DAPSA, Disease Activity Index for Psoriatic Arthritis; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; nr-axSpA, non-radiographic axSpA; PBO, placebo; r-axSpA, radiographic axSpA; REM, remission; SJC, swollen joint count.
非 KM Figure
Figure 6Proportion of patients achieving SJC=0 and combined SJC=0 and TJC=0 response (non-responder imputation). Randomised set. SJC and TJC assessed in 44 joints. Reported in patients with SJC>0 at baseline. axSpA, axial spondyloarthritis; BKZ, bimekizumab; nr-axSpA, non-radiographic axSpA; PBO, placebo; Q4W, every 4 weeks; r-axSpA, radiographic axSpA; SJC, swollen joint count; TJC, tender joint count.
非 KM Figure
Figure 7Change from baseline in clinical outcomes at week 104, stratified by MASES resolution at week 104 (observed case). All bimekizumab-randomised patients with MASES>0 at baseline. Error bars represent 95% CIs. ASQoL, Ankylosing Spondylitis Quality of Life; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CI: confidence interval; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; nr-axSpA, non-radiographic axSpA; NSP, nocturnal spinal pain; r-axSpA, radiographic axSpA; TSP, total spinal pain.
非 KM Figure